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Dear Editor:
Intravascular large B-cell lymphoma (B-IVL) is listed
as a distinct disease entity in the World Health Organi-
zation(WHO) classification for lymphoid neoplasms [1].
The disease is rare, and information for its exact fre-
quency among non-Hodgkin lymphoma (NHL) has been
extremely limited. There have been several reports
mainly from Asian countries describing the different dis-
ease frequencies [2-4]. In addition, population of the
cases was variously described among these reports.
Therefore it is difficult to know the geographical differ-
ence in disease frequency, which might be helpful for
understanding pathogenesis of disease.
From November 1999 to December 2010, a total of
5,085 cases were registered with the Osaka Lymphoma
Study Group (OLSG), which was established in 1999,
and more than 60 institutes in Osaka area, Japan partici-
pate to it. All of the hematoxylin and eosin-and immu-
noperoxidase-stained sections were reviewed by one of
the authors (KA). A diagnosis of malignant lymphoma
was confirmed in 4,066 cases (80.0%). Of these 4,066
cases, 3,726 (91.6%) were NHL and 340 (8.4%) Hodgkin
lymphoma. Number of cases with DLBCL and B-IVL
was 1,815(44.6% of all ML, 48.7% of NHL) and 9(0.22%
of all ML, 0.24% of NHL), respectively. Histologic cri-
teria for the diagnosis of B-IVL is selective growth of B-
lymphoid cells, usually with large size, within lumina of
small or intermediated vessels.
9 cases of B-IVL in OLSG were summarized in Table 1.
The median age of the B-IVL patients (67 years old) at
biopsy for diagnosis in the present series was similar to
that of the previous reports from Japan and Italy, but
slightly older than that from Thailand [4-6]. Females
predominated males remarkably in the present series.
Frequency of presence of neurological and B-symptoms
was rather similar among present and the previous
reports from Asian countries and Italy [4-6]. Whereas
cutaneous lesions were more frequently found in Italy
compared to Asian countries. Lymphadenopathy and
hepatosplenomegaly were more frequently found in
Asian than in Western cases [4-6]. Recently, Japanese
investigators reported that frequencies of neurological
symptoms and cutaneous lesions were low but that of
hemophagocytic syndrome was high in B-IVL of Asian
countries, and advocated the term “Asian variant of B-
IVL” [5,7-10]. But as shown in Table 2, these findings
were not discriminating ones to distinguish Asian from
Italian cases into different category. It is rather a differ-
ence of frequency, not justifying B-IVL in Asian countries
as Asian variant. The frequency of hemophagocytosis was
relatively low (19%) in Sanya et al’s cases from Thailand,
whereas it was high (61%) in Murase et al’s cases [4,5].
The common site for biopsy was lung in the present ser-
ies, whereas bone marrow in Murase’sa n dS a n y a ’s series
[4,5]. The present patients were treated with chemother-
apy mostly with rituxan. Two patients received auto per-
ipheral blood stem cell transplantation and radiotherapy.
Follow-up duration in 8 patients diagnosed by biopsy
ranged from 18.6 to 111.8(median 30.6) months for the 5
survivors. Three-year survival rate was 67%.
The frequency of B-IVL among NHL was 0.24% in the
present series, and that in the previous reports from
Japan, Hong Kong, and Thailand was 0.1%, 0.31%, and
0.91%, respectively [2-4]. Whether the differences in fre-
quency among Asian countries might be due to collec-
tion bias, i.e., use of randomly collected cases, inclusion
of consultation cases, or serially registered cases, or
reflect real difference in the disease incidence among
these countries could not be judged based on the data
shown in the previous literature. Present study is based
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reflecting the real frequency of B-IVL in Japan.
According to the statistics (Center for Cancer Control
and Information Services, National Cancer Center,
Japan, 2005), approximately 15,560 persons are newly
diagnosed in Japan as having NHL annually [11]. Based
on the data presented by the Lymphoma Study Group
of Japanese Pathologists [3] or the OLSG, it is postu-
lated that only 16 or 37 persons are diagnosed as B-IVL
in Japan annually. When adopting the former data, 16
p e r s o n s ,aw h o l eo fn e w l yd i a g n o s e dc a s e si nJ a p a nf o r
approximately 6 and 12.5 years must be collected to
obtain approximately 100 and 200 cases of B-IVL,
respectively. For this, extensive collaborative study is
indispensable.
In conclusion, formal epidemiologic study is necessary
to know the difference of B-IVL among each area.
There are some differences in frequency of symptoms
among each district, but it does not necessarily mean
the presence of specific variant in some area.
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f:female, m: male
THP-COP: pirarubicin, cyclophosphamide, vincristine and prednisolone
R-CHOP: rituximab-cyclophosphamide, doxorubicin, vincristine, and
prednisone
R-THP-COP: rituximab-pirarubicin, cyclophosphamide, vincristine and
prednisolone
PBSC: peripheral blood stem cell transplantation
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